
Health authorities have initiated a targeted vaccination initiative to administer meningitis B vaccines to approximately one million young people during the coming summer months. The program is designed to address rising concerns about meningococcal disease cases in this age group.
Meningitis is an infection affecting the protective membranes surrounding the brain and spinal cord. The disease can develop suddenly and present various symptoms including high fever, severe headache, stiff neck, rash that does not fade under pressure, vomiting, diarrhea, joint and muscle pain, light sensitivity, and in severe cases, seizures or confusion. Bacterial meningitis is less common than viral forms but significantly more dangerous, potentially leading to blood poisoning and brain damage. Meningitis B accounts for the majority of severe meningococcal disease cases in the UK, with 378 cases of invasive meningococcal disease recorded in the 2024-2025 period.
The transmission of meningitis typically occurs through close personal contact. Infected individuals can spread the bacteria through respiratory droplets released during coughing, sneezing, or kissing, or through sharing items like drinks or vapes. Notably, some people may carry the bacteria in their nose or throat without becoming ill while still transmitting it to others. University and residential settings present elevated transmission risk due to shared accommodation conditions.
The vaccination program targets Year 13 pupils preparing to leave school and individuals under 25 entering university or residential further education for the first time. Two doses of the MenB vaccine will be provided free through the National Health Service. Experts note this population faces higher risk due to communal living arrangements, with disease cases typically peaking in October and November. Medical professionals stress that anyone experiencing meningitis symptoms should seek emergency care immediately, as early treatment can be lifesaving.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI